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Abstract
        Bayer 41-4109 is heteroarylpyrimidine (HAP) which has been identified as potent  of HBV capsid assembly
inhibitor. The present study was  to study effect of Bayer 41-4109 treatment on the intracellular localization of
EGFP-Core fusion proteins into HepG2 cells. Three recombinant plasmids of pEGFP-Core with single, double and
triple NLS of HBV core (EGFP-Core 1C, 2C and 3C ) and two recombinant plasmids with single and triple NLS of
SV-40 (EGFP-Core 1 and 3 SV-40) were used in this work. After transient transfected into HepG2 cells and treated
with Bayer 41-4109, the intracellular localization of expressed fusion proteins from all plasmid constructions were
determined and quantified under confocal laser microscope. Results shown that Bayer 41-4109 treatment in HepG2
cells inhibited the nuclear localization of EGFP-Core with single of triple HBV core  NLS. As well as the construc-
tions of expressed fusion protein with single and triple SV-40 NLS (EGFP-Core 1 and 3 SV-40 NLS) showed
decreasing  the nuclear localization after treated with Bayer 41-4109, even not as strong as EGFP-Core 1C and 3C
NLS. Bayer 41-4109 has been identified as a potent inhibitors of HBV replication which has multiple effects on HBV
capsid assembly. It may inhibit virus replication by inducing assembly inappropriately and  by misdirecting
assembly decreasing the stability of normal capsids.
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Introduction
Hepatitis B virus (HBV) infects chroni-
cally more than 400 million people world-
wide. Chronic HBV infections the major risk
factor for liver cancer called hepatocellular
carcinoma or HCC (Hollinger, 1996). HBV
is an enveloped DNA virus with an icosa-
hedral capsid or core. The HBV capsid is
assembled in the cytoplasm from core pro-
tein, viral pregenome RNA, viral reverse
transcriptase and few host proteins. The
core protein plays an important roles in vi-
ral DNA synthesis from pregenome and in-
tracellular tracfficking in the nucleus
(Ganem and Schneider, 2001).
HBV persistence and transmission re-
quire HBV replication, which depends on
the assembly of a core particle composed of
capsid protein (Cp), polymerase, and
pregenomic RNA. Reverse transcription to
produce infectious DNA-containing par-
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ticles occurs solely within the core residing
in the cytoplasm (Ganem and Schneider,
2001, Seeger and Mason, 2000). HBV core
assembly is likely to be a high value target
for therapeutics (Zlotnick and Stray, 2003).
Approval treatments for chronic HBV
are IFN-a and the polymerase inhibitors
lamivudine or adefovir (Karayiannis 2004,
Wands, 2004). IFN-a therapy has limited
efficacy (Brunetto et al., 1993). Resistant vi-
ruses arise during treatment with poly-
merase inhibitors (Ling et al., 1996, Villeneue
et al., 2003), with rates for lamivudine resis-
tance approaching 50% (Karayiannis, et al.,
2004, Liaw et al., 2004). The most of antivi-
ral strategy against HBV is to attack the re-
verse transcriptase. An alternative therapeu-
tic strategy would be targeting capsid as-
sembly (Zlotnick et al., 2002).
 Heteroaryldihydropyrimidines (HAPs),
first identified by scientists at Bayer com-
pany as having anti-HBV activity in a cell
culture-based screen, act in a capsid pro-
tein-specific manner (Deres et al., 2003;
Stray et al., 2005). HAP as a novel class of
HBV inhibitors in tissue culture and animal
models, effective at nanomolar concentra-
tion (Weber et al., 2002). The mechanism of
HAP activity has been studied in vitro us-
ing the 149-residue assembly domain of the
HBV capsid protein (Hacker et al., 2003;
Stray et al., 2005).
Bayer 41-4109 is also referred to as
heteroaryldihydropyrimidine or HAP. This
compound has been tested in cell culture
and animal model (Weber et al., 2002), and
on HBV capsid assembly in vitro. Bayer 41-
4109 is discovered as highly potent non-
nucleosidic inhibitors of HBV replication
both in vitro and in vivo (Weber et al., 2002).
As another antiviral, HAP work to prevent
the proper formation of HBV core particles
(nucleocapsid), which are the site of viral
DNA replication (King et al., 1998). Core
particles are stable and they have high mo-
lecular weight aggregates assembled from
HBV core protein subunits (Nassal, 1992).
The chemical structure of Bayer 41-4109
that used in this work more detail could be
shown in figure 1. The inhibitory concen-
tration of Bayer 41-4109 needed to decrease
HBV genome replication by 50% (IC50) in
stably transfected HepG2.2.15 cells or HBV-
producing hepatoma cells (Sells et al., 1987).
Figure 1. Structures of Bayer 41-4109 is a
heteroaryldihydropyrimidine or HAP according to
Weber et al., 2002.  Structure of Bayer 41-4109 is as a
pure (-) enantiomer or R enantiomer.
Here, we report the of HBV capsid as-
sembly inhibitor Bayer 41-4109 as a
heteroaryldihydropyrimidine (HAP) on the
intracellular localization of EGFP-Core fu-
sion proteins. We also reported the quanti-
fication of EGFP-Core fusion protein with
redundant single and triple NLS of HBV
core and SV-40  which expressed as fusion
protein in the cell compartments.
Materials and Methods
Materials of this study are HBV core
fusion protein encoding DNA plasmid with
redundant NLS of HBV core and SV-40
which have been prepared by Haryanto and
Kann (2006), HBV capsid assembly inhibi-
tor Bayer 41-4109 (Bayer AG), transfection
agent Tfx-20 (PROMEGA), hepatocyte cell
line HepG2, DMEM medium (GIBCO-BRL)
and Fetal Calf Serum or FCS (GIBCO-BRL).
Design of EGFP-Core Fusion Protein Encod-
ing Plasmids with redundant NLS of HBV
core and SV-40.
The recombinant plasmid pEGFP-Core
with single, double and triple NLS of HBV
core (EGFP-Core 1C, 2C and 3C ) as well as
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the recombinant plasmid with double and
triple NLS of SV-40 (EGFP-Core 2 and 3 SV-
40) were designed by Haryanto et al, (2007),
which used as original recombinant DNA
plasmid.
Preparation of hepatocyte cell line HepG2
for Transfection
In 24 well plat, HepG2 cells was grown
onto collagenized cover slips one day before
transfection. The cell lines were incubated
over night at 37°C in incubator CO2 until
75-80% confluent.
Transfection and treatment of Bayer 41-
4109
All construction of recombinant DNA
plasmid were transfected into HepG2 cells.
The transfection reaction consist of 5 ìl DNA
plasmid (200 ng/ìl), 5 ìl Tfx-20 and 300 ìl
serum free medium. Then it was mixed gen-
tly and incubated at room temperature for
5-10 minutes. While, 24 well plat were took
out from CO2 incubator and changed the
10% FCS containing medium with serum
free medium. 24 well plat was returned to
the CO2 incubator and continued the incu-
bation for the appropriate length of time
before transfection. Transfection was done,
by replacing serum free medium with the
mixture of DNA/Tfx-20 reagent/FCS free
medium 310 ìl per well. The 24 well plate
was incubated in the CO2 incubator at 37
°C for 1 hour. During incubation the 10%
FCS containing medium was warmed at
37°C in the waterbath and Bayer 41-4109
in final concentration of 10 nM/ml was di-
rectly added in DMEM medium. Then the
well plat was incubated into the CO2 incu-
bator at 37°C over night.
Indirect immunostaining and confocal la-
ser microscopy.
The transfected cells was immune
stained with mouse monoclonal antibody
414 anti NPC (1:500) as primary antibody
and labeled with secondary antibody anti
mouse, which marked texas red dye (1:100).
Then the intracellular localization of EGFP-
Core fusion protein determined under con-
focal laser microscope as described before
by Haryanto (2006).
Quantification of intracellular localization
The HBV core fusion protein which
found localized in the compartment of
HepG2 cells, was quantified manually us-
ing confocal laser scann microscope. The
Amount of HBV core protein that distrib-
uted in the cytoplasm, nucleus or both of
cell compartment were quantified in the
absolute and relative values.
Results and Discussion
Recently, an assembly inhibitor of HBV
capsids was found (Deres et al., 2003). This
inhibitor interacts with capsid formation.
However, the site of interaction and the
stage at which assembly is blocked dimer-
ization of the capsid protein monomers or
the trimerization of the dimers  is yet un-
clear. Mature HBV particles consists of a 3,5
kb partially single stranded circular genome
and a single copy of the viral reverse tran-
scriptase (RT) encapsidated in an icosahe-
dral protein composed of 120 HBV capsid
protein or Cp dimmers, host chaperons and
kinases may also be incorporated (Seeger
and Mason, 2000).
First, the HBV genome was transfected
into HuH-7 cells as described before. Twenty
four hours after transfection, the inhibitor
was added to one sample whereas a sec-
ond one remained untreated. The success-
ful inhibitor treatment was determined by
real time PCR. Supernatant of cell culture
was analyzed 48 hours post transfection.
Unencapsidated viral DNA, as it may be
have been derived from transfected ge-
nomes sticking to the dish or from lysed
cells, was degraded prior to purification of
viral DNA .
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Real time PCR was done in triplets
showing the addition of the inhibitor re-
duced the number of encapsidated viral
genomes to 60%. This inhibition rate was
significantly smaller than the one published
for HepG2.2.15 cells in which virus secre-
tion was reduced six fold (Deres et al., 2003).
This difference may either mean that the cell
type or may play a role, for instance that
HuH-7 can export the inhibitor more effi-
ciently than HepG2 cells. However, since the
transfected HBV genome is genotype A and
HepG2.2.15 cells express HBV of genotype
D a genotype-specific binding of the inhibi-
tor could not be excluded.
Then the effect of the inhibitor on local-
ization of the fusion proteins was investi-
gated. The experimental procedure was
done as described before but the inhibitor
was added after over night incubation fol-
lowing transfection. NPCs were stained af-
ter further 24 hours of incubation. As
decribed before that structure of Bayer 41-
4109 is an (-) enantiomer, binding of Bayer
41-4109 to HBV core protein the is ste-
reospecific, with only the (-) enantiomer
capable of binding to HBV core particles
(Deres et al., 2003).
Figure 2 and 3 showed a changed dis-
tribution pattern within the nucleus. In con-
trast enrichment in defined areas the
nuclear fluorescence filled the entire karyo-
plasm with the exception of some nucleoli-
shaped areas.
Figure 2. Localization of EGFP-Core 1C, 2C, 3C in
HepG2 cells.  The fusion protein localized in cyto-
plasm (upper row), nucleus (middle row) and both
cytoplasm and nucleus (lower row) in EGFP-Core 1C
and 2 SV40 NLS.  In EGFP-Core 2C, 3C and 3 SV40
NLS localized only in cytoplasm (upper row), nucleus
(upper row). The fusion proteins are shown as green
fluorescence, the nuclear pore complexes in red.
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Figure 3. Localization of EGFP-Core  2 SV-40 NLS and
3 SV-40 NLS in HepG2 cells.  The fusion protein local-
ized in cytoplasm (upper row), nucleus (middle row)
and both cytoplasm and nucleus (lower row) in EGFP-
Core 1C and 2 SV40 NLS.  In EGFP-Core 2C, 3C and 3
SV40 NLS localized only in cytoplasm (upper row),
nucleus (upper row). The fusion proteins are shown
as green fluorescence, the nuclear pore complexes in
red.
When quantifying the number of cells
with cytoplasmic and nuclear localization
of fluorescence fusion protein (see more de-
tail in the Table) a striking difference for the
EGFP-core fusion proteins compared to
capsid localization was observed. While
EGFP-core 1C showed a nuclear localiza-
tion in 52% of the untreated cells, Bayer 41-
4109 treated cells showed a nuclear local-
ization in only 11%. The same ratio or even
more pronounced was observed for EGFP-
Core 3C (57% versus 4%).
Table. Localization of  fusion protein EGFP-Core 1C,
3C and EGFP-Core 2, 3 SV40 NLS fusion protein in
Bayer 41-4109-treated and untreated Hep G2 cells.
In Table shown that Bayer 41-4109
treatment in HepG2 cells inhibited the
nuclear localization of EGFP-Core with
single of triple HBV core  NLS. As well as
the constructions of expressed fusion pro-
tein with single and triple SV-40 NLS
(EGFP-Core 2 and 3 SV-40 NLS) showed
decreasing  the nuclear localization after
treated with Bayer 41-4109, even not as
strong as EGFP-Core 1C and 3C NLS. It
shown that Bayer 41-4109 which is a mem-
ber of a class of HAP has been identified as
a potent inhibitors of HBV replication.
Bayer 41-4109 has multiple effects on HBV
capsid assembly. It may inhibit virus repli-
cation by inducing assembly inappropriately
and  by misdirecting assembly decreasing
the stability of normal capsids (Stray and
Zlotnick, 2006).
Apparently, dimerization increases the
nuclear transport capacity of the fusion pro-
teins. The effect of dimerization was much
more pronounced when adding an addi-
tional NLS to the fusion protein. In contrast,
the effect of the inhibitor on EGFP-Core
SV40 NLS protein localization was not sig-
nificant. Although the percentage of cells
with cytoplasmic fluorescence increased in
the inhibitor treated cells for both EGFP-
Core 1 SV40 NLS and EGFP-Core 3 SV40
NLS, this difference was only marginal and
with 10% not above the variation occurring
between different transfections. The differ-
ence between the EGFP-Core 1, 3C and
EGFP-Core 1, 3 SV40 NLS may imply that
the inhibitor interacts with the C-terminus
of the capsid protein preventing binding of
importin  a to the NLS. This area overlaps
with the nucleic acid binding domain
(Hatton et al., 1992) of the capsid protein
that stabilizes the capsid. As it was shown
previously for DHBV capsids, mutations
within this domain destabilize the viral
capsid. It must be thus assumed that the
described effect on capsid formation by
Deres et al., (2003) is not necessarily a di-
rect inhibition of assembly but may cause a
reduced stability.
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